Literature DB >> 24047747

The first report on the outbreak of OXA-24/40-like carbapenemase-producing Acinetobacter baumannii in Turkey.

Ayşe Nur Sarı1, Meral Biçmen, Zeynep Gülay.   

Abstract

Carbapenem resistance due to OXA-type carbapenemases seriously limits therapeutic options in nosocomial infections caused by Acinetobacter baumannii. Previous studies have shown the presence of OXA-51, OXA-58, and OXA-23 carbapenemases but not OXA-24/40 in A. baumannii in Turkey. In this study, we investigated carbapenem-hydrolyzing class D β-lactamases (CHDLs) in A. baumannii and the molecular epidemiology of CHDL producers at the Dokuz Eylul Hospital, Izmir Turkey, and detected blaOXA-24/40 in a clinical isolate from a patient in the medical intensive care unit (ICU). The specific enzyme type was OXA-72. Additional studies revealed 22 more isolates from 20 patients and that the OXA-72-producing strain caused an outbreak in the medical ICU from September 2012 to March 2013, which still continues. To our knowledge, this is the first report of OXA-24/40 carbapenemases in A. baumannii in Turkey. Emergency infection control should be implemented following the arrival of a new OXA at a hospital where A. baumannii is highly endemic.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047747

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  9 in total

1.  Investigation of Metallo Beta Lactamases and Oxacilinases in Carbapenem Resistant Acinetobacter baumannii Strains Isolated from Inpatients.

Authors:  M Duygu Aksoy; Şaban Çavuşlu; H Murat Tuğrul
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

2.  Specific Amino Acid Substitutions in OXA-51-Type β-Lactamase Enhance Catalytic Activity to a Level Comparable to Carbapenemase OXA-23 and OXA-24/40.

Authors:  Kwan-Wai Chan; Chen-Yu Liu; Ho-Yin Wong; Wai-Chi Chan; Kwok-Yin Wong; Sheng Chen
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

3.  Spread of carbapenem-resistant international clones of Acinetobacter baumannii in Turkey and Azerbaijan: a collaborative study.

Authors:  S S Ahmed; E Alp; A Ulu-Kilic; G Dinc; Z Aktas; B Ada; F Bagirova; I Baran; Y Ersoy; S Esen; T G Guven; J Hopman; S Hosoglu; F Koksal; E Parlak; A N Yalcin; G Yilmaz; A Voss; W Melchers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-04       Impact factor: 3.267

4.  Characterization of Carbapenemases in Extensively Drug Resistance Acinetobacter baumannii in a Burn Care Center in Iran.

Authors:  Leila Azimi; Malihe Talebi; Mohammad-Reza Pourshafie; Parviz Owlia; Abdolaziz Rastegar Lari
Journal:  Int J Mol Cell Med       Date:  2015

5.  High prevalence and clonal dissemination of OXA-72-producing Acinetobacter baumannii in a Chinese hospital: a cross sectional study.

Authors:  Yong Chen; Yuying Yang; Lin Liu; Guangbin Qiu; Xuelin Han; Shuguang Tian; Jingya Zhao; Fangyan Chen; Hajo Grundmann; Haifeng Li; Jinke Sun; Li Han
Journal:  BMC Infect Dis       Date:  2018-09-29       Impact factor: 3.090

6.  Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations.

Authors:  Raghdaa A Ramadan; Manar G Gebriel; Heba M Kadry; Ahmed Mosallem
Journal:  Infect Drug Resist       Date:  2018-08-22       Impact factor: 4.003

7.  Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii.

Authors:  Mohammad Hamidian; Steven J Nigro
Journal:  Microb Genom       Date:  2019-10

8.  Co-infection of ST2IP carbapenem-resistant Acinetobacter baumannii with SARS-CoV-2 in the patients admitted to a Tehran tertiary referral hospital.

Authors:  Alireza Abdollahi; Amir Aliramezani; Mohammadreza Salehi; Mahsa Norouzi Shadehi; Sedighe Ghourchian; Masoumeh Douraghi
Journal:  BMC Infect Dis       Date:  2021-09-08       Impact factor: 3.090

9.  The First Outbreak Caused by Acinetobacter baumannii ST208 and ST195 in China.

Authors:  Junyan Qu; Yu Du; Rujia Yu; Xiaoju Lü
Journal:  Biomed Res Int       Date:  2016-04-10       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.